Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA-4
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siRNA-4 is a specific small interfering RNA (siRNA) sequence utilized in preclinical research to target and silence the expression of Insulin-like growth factor binding protein 2 (IGFBP2). In the context of ovarian cancer studies, siRNA-4 has been employed to investigate the role of IGFBP2 in promoting tumor cell invasion and migration. By binding to the complementary sequence of IGFBP2 mRNA, siRNA-4 facilitates its cleavage and degradation via the RNA-induced silencing complex (RISC), thereby reducing the levels of the IGFBP2 protein. This experimental agent has helped identify IGFBP2 as a potential therapeutic target in malignancies where it is overexpressed, such as ovarian cancer.
- Other names
- IGFBP2 siRNA-4IGFBP-2 siRNA-4IGFBP 2 siRNA-4
02
Targets
IGFBP2 (Insulin-like growth factor binding protein II)
Beyond the preview
Go deeper on siRNA-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA-4.